EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Pyridostigmine Treatment for Pediatric Axonal Guillain–Barré Syndrome

E Zohar-Dayan iD, J Landa, S Barak iD, B Ben-Zeev

Muscle & Nerve · 2026

DOI: 10.1002/mus.70153 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Muscle & Nerve, 2026. Verfasst von E Zohar-Dayan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurologic Unit, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medica Center, Tel Hashomer, Ramat-Gan, Israel. Hauptthemen laut MEDLINE: Pyridostigmine Bromide, Cholinesterase Inhibitors, Guillain-Barre Syndrome, Axons. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Direct involvement of the neuromuscular junction (NMJ) in the inflammatory process of Guillain–Barré syndrome (GBS) has been described. Despite this, the NMJ very rarely serves as a target for direct medical intervention in GBS. Here, we report the use of an acetylcholinesterase inhibitor, pyridostigmine, in four pediatric patients with axonal GBS.

Methods

All patients received standard immune therapy. Pyridostigmine treatment was started 7 weeks to 5 months after disease onset, and 5–11 weeks from reaching the plateau phase. Treatment efficacy was monitored by the 6‐min walk, quadriceps femoris and hamstring strength (manual muscle testing), the pediatric evaluation of disability inventory‐functional skills, and the GBS disability score. All tests were performed before and during drug intervention.

Results

All treated patients showed marked improvement in their motor and functional abilities. After 1 month of treatment, quadriceps femoris and hamstring strength increased by at least two points, and walking distance increased by 10–272 m. The pediatric evaluation of disability inventory functional skills mobility test increased by 22.3–34.7 points. No serious side effects were documented.

Discussion

Pyridostigmine may be a safe and effective add‐on treatment in pediatric patients with axonal GBS who show insufficient response to immune therapy, and may be effectively used even at a late stage. Additional, larger studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pyridostigmine BromideCholinesterase InhibitorsGuillain-Barre SyndromeAxonsHumansFemaleMaleChildTreatment OutcomeAdolescentMuscle StrengthDisability Evaluation

Stichwörter der Autor:innen

Guillain–Barré syndromeacetylcholinesterase inhibitorinterventionsneuromuscular junctionpyridostigmine

Substanzen

Pyridostigmine BromideCholinesterase Inhibitors

Autor:innen und Institutionen

  • Pediatric Neurologic Unit, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medica Center, Tel Hashomer, Ramat-Gan, Israel.
  • Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Department of Pediatric Rehabilitation, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medica Center, Tel Hashomer, Ramat-Gan, Israel.
  • Department of Nursing, Faculty of Health Sciences, Ariel University, Ariel, Israel.

ORCID-Profile: E Zohar-Dayan, S Barak

Zitieren

APA

Zohar-Dayan, E., Landa, J., Barak, S., & Ben-Zeev, B. (2026). Pyridostigmine Treatment for Pediatric Axonal Guillain–Barré Syndrome. Muscle & Nerve. https://doi.org/10.1002/mus.70153

Vancouver

Zohar-Dayan E, Landa J, Barak S, Ben-Zeev B. Pyridostigmine Treatment for Pediatric Axonal Guillain–Barré Syndrome. Muscle & Nerve. 2026. doi:10.1002/mus.70153

BibTeX
@article{ZoharDayan2026,
  author = {Zohar-Dayan, E and Landa, J and Barak, S and Ben-Zeev, B},
  title = {Pyridostigmine Treatment for Pediatric Axonal Guillain–Barré Syndrome},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70153}
}
Kostenlos starten →